Herdeg C, Oberhoff M, Baumbach A, Blattner A, Axel D I, Schröder S, Heinle H, Karsch K R
Department of Medicine, University of Tuebingen, Germany.
J Am Coll Cardiol. 2000 Jun;35(7):1969-76. doi: 10.1016/s0735-1097(00)00614-8.
The aim of this study was to evaluate the potential of paclitaxel to prevent restenosis in vivo.
Paclitaxel (Taxol) is a microtubule-stabilizing compound with potent antitumor activity. It influences the cytoskeleton equilibrium by increasing the assembly of altered microtubules, thereby inducing cellular modifications that result in reduced proliferation, migration and signal transduction.
Before the in vivo study, delivery efficiency was determined with radiolabeled paclitaxel in porcine hearts. After induction of a defined plaque in the right carotid arteries of 76 New Zealand rabbits by electrical stimulation, 27 animals underwent balloon dilation and subsequent local paclitaxel delivery (10 ml, 10 micromol/liter) with a double-balloon catheter. Twenty-nine animals served as control with angioplasty only, 10 animals underwent local delivery of vehicle only (0.9% NaCl solution) and 10 animals were solely electrostimulated. Vessels were excised one, four, and eight weeks after intervention.
The extent of stenosis in paclitaxel-treated animals was significantly reduced compared with balloon-dilated control animals (p = 0.0012, one, four and eight weeks after intervention: 14.6%, 24.6% and 20.5%, vs. 24.9%, 33.8% and 43.1%, respectively). Marked vessel enlargement compared with balloon-dilated control animals could be observed (p = 0.0001, total vessel area after one, four and eight weeks: paclitaxel group: 1.983, 1.700 and 1.602 mm2, control: 1.071, 1.338 and 1.206 mm2, respectively). Tubulin staining and electron microscopy revealed changes in microtubule assembly, which were limited to the intimal area. Vasocontractile function after paclitaxel treatment showed major impairment.
Local delivery of paclitaxel resulted in reduced neointimal stenosis and enlargement in vessel size. Both these effects contribute to a preservation of vessel shape and are likely to be caused by a structural alteration of the cytoskeleton.
本研究旨在评估紫杉醇在体内预防再狭窄的潜力。
紫杉醇是一种具有强大抗肿瘤活性的微管稳定化合物。它通过增加异常微管的组装来影响细胞骨架平衡,从而诱导细胞发生改变,导致增殖、迁移和信号转导减少。
在体内研究之前,用放射性标记的紫杉醇在猪心脏中测定给药效率。通过电刺激在76只新西兰兔的右颈动脉中诱导出明确的斑块后,27只动物接受球囊扩张并随后用双球囊导管进行局部紫杉醇给药(10毫升,10微摩尔/升)。29只动物仅接受血管成形术作为对照,10只动物仅接受局部赋形剂给药(0.9%氯化钠溶液),10只动物仅接受电刺激。干预后1周、4周和8周切除血管。
与球囊扩张的对照动物相比,紫杉醇治疗动物的狭窄程度显著降低(p = 0.0012,干预后1周、4周和8周:分别为14.6%、24.6%和20.5%,而对照为24.9%、33.8%和43.1%)。与球囊扩张的对照动物相比,可以观察到明显的血管扩张(p = 0.0001,1周、4周和8周后的总血管面积:紫杉醇组分别为1.983、1.700和1.602平方毫米,对照组分别为1.071、1.338和1.206平方毫米)。微管蛋白染色和电子显微镜显示微管组装发生变化,仅限于内膜区域。紫杉醇治疗后的血管收缩功能显示出严重受损。
局部给予紫杉醇可减少新生内膜狭窄并增大血管尺寸。这两种作用都有助于维持血管形状,并且可能是由细胞骨架的结构改变引起的。